Robert F. Kennedy Jr.'s Advisory Committee on Immunization Practices voted to recommend clesrovimab, an RSV vaccine for infants 8 months and younger lacking maternal vaccine protection. This comes as part of a broader review of childhood immunization schedules. Merck's ENFLONSIA is seen as a vital preventive measure against RSV, which infects nearly all children by age two and causes significant health risks, including around 300 deaths annually in the U.S. The new committee, selected by RFK, includes known vaccine skeptics, marking a shift in vaccine policy discussions.
The Advisory Committee on Immunization Practices (ACIP) recommended clesrovimab, a new RSV antibody shot for infants without maternal vaccine protection, marking a significant stance by RFK.
Dr. Dean Y. Li emphasized the importance of ENFLONSIA in preventing RSV in infants, aiming to alleviate the burden of this widespread infection.
The vote for the RSV vaccine was significant as it was the first from a new committee formed by RFK, which includes members with vaccine skepticism.
RSV leads to nearly universal infection in children by age 2, and it causes approximately 300 infant deaths annually in the U.S.
Collection
[
|
...
]